Interesting ImagesRenal Medullary Carcinoma on Dual-Time Point FDG PET/CT ImagingHou, Guozhu MD*,†; Jiang, Yuanyuan MD*,†; Wang, Jing MD‡; Li, Fang MD*,†; Cheng, Wuying MD*,†Author Information From the *Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College †Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine ‡Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Received for publication October 22, 2019; revision accepted February 15, 2020. G.H. and Y.J. contributed equally to this work. Conflicts of interest and sources of funding: This work is supported by National Natural Science Foundation of China (nos. 81371588 and 81101074). None declared to all authors. Correspondence to: Wuying Cheng, MD, Department of Nuclear Medicine, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China. E-mail: firstname.lastname@example.org. Online date: April 23, 2020 Clinical Nuclear Medicine: June 2020 - Volume 45 - Issue 6 - p 446-447 doi: 10.1097/RLU.0000000000003033 Buy Metrics Abstract Renal medullary carcinoma is a rare and highly aggressive tumor seen almost exclusively in young individuals of African descent with sickle cell disease. Here, we describe a case of a 29-year-old man, who did not have sickle cell disease, with pathologically confirmed renal medullary carcinoma using dual-time FDG PET/CT. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.